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D
iabetic macular edema (DME) is the leading cause of blindness in diabetic patients in developed countries. 1, 2 In diabetes mellitus, DME has been reported in 4.8% to 6.8% of patients. 3, 4 Serous retinal detachment (SRD) is very common in DME. 5, 6 In recent studies, SRD has been reported in 13% to 45% of cases. [6] [7] [8] [9] In recent years, intravitreal injections of anti-VEGF have become the first-line therapy for central DME with impaired visual acuity (VA). [10] [11] [12] Previous studies have described the natural course, 13 pathogenesis, and visual outcome of SRD associated with DME. However, among the patients treated with ranibizumab for DME, the effect of SRD remains unclear.
We have previously found 9 that SRD was associated with a higher gain of VA 6 months after treatment with ranibizumab. However, in eyes with DME and SRD, the baseline BCVA was significantly lower.
The aim of this study was to determine whether the higher VA gain after DME treatment in the presence of SRD was due to the SRD itself or was a consequence of the lower baseline VA.
METHODS
All diabetic patients treated for DME in our department from November 2013 to November 2014 were retrospectively included. An informed consent was obtained from all patients.
Inclusion criteria were age >18 years, type 1 or 2 diabetes with HbA1C <12%, central retinal thickness (CRT) ‡300 lm on the optical coherence tomography (OCT) B-Scan images, bestcorrected VA (BCVA) score 70 letters based on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, and patients who had received at least the loading dose of 3 monthly injections. Patients with a history of pan retinal photocoagulation and/or focal/grid laser photocoagulation were eligible. When both eyes of a patient had DME, only the right eye was included.
Exclusion criteria were proliferative diabetic retinopathy, intravitreal hemorrhage or diabetic tractional retinal detachment, ischemic maculopathy, previous intravitreal steroids or bevacizumab injections during the last 6 months, thromboembolic arterial event during the last 3 months, pregnancy, intraocular pressure (IOP) >24 mm Hg on medication, uveitis or other vitreoretinal pathology, or other condition that could contribute to the visual decrease.
All patients underwent a complete ophthalmologic examination including BCVA, slit-lamp, and noncontact fundus examination (Superfield; Volk, Mentor, OH, USA). Fluorescein angiography (FA; Topcon TRC-50DX Retinal Camera, Topcon Medical Systems, Inc., Tokyo, Japan) and OCT (OPKO OCT/ SLO, OPKO Health, Inc., OTI, Miami, FL, USA) were performed at baseline. DME was defined by a CRT ‡300 lm and the absence of foveal pit. Baseline FA was performed to rule out ischemic maculopathy.
The presence of an SRD was confirmed by OCT by the presence of subretinal fluid between the retina and the retinal pigment epithelium.
Patients were divided into two groups: DME with SRD (SRDþ group) and DME without SRD (SRDÀ group). Patients were adjusted on their baseline BCVA: for each DME patient with SRD, a DME patient without SRD with the same baseline BCVA was randomly included.
All patients received a loading dose of 3 monthly injections of ranibizumab, followed by retreatments with an as-needed basis (PRN regimen). For this pro re nata (RPN) regimen, we performed monthly injections until VA stability was achieved for a period of at least two consecutive visits or until normal VA was achieved. When the stability was reached, treatment with ranibizumab was interrupted. If VA deteriorated (greater than five letters), monthly injections were reinitiated until stability was again achieved. 14 Patients were examined every 4 weeks. At each visit, the BCVA was assessed using the ETDRS chart, and fundus photography and spectral-domain optical coherence tomography were performed.
The efficacy of the treatment was based on functional and anatomical responses to ranibizumab.
The primary endpoint was the difference in mean BCVA change between the SRDþ and SRDÀ groups from baseline to month 12 (M12).
Secondary endpoints were the difference in mean CRT change between the SRDþ and SRDÀ groups from baseline to M12, number of intravitreal injections, and proportion of patients who gained or lost ‡15 letters.
Statistical analyses were performed using a t-test for numerical values and a v 2 test for percentages. A P value < 0.05 was considered statistically significant. All tests were twosided at a 0.05 significance level. Analyses were carried out using R statistical software version 2.15.2.
RESULTS
Seventy-eight eyes of 78 patients were included: 39 eyes in the SRDþ group and 39 eyes in the SRDÀ group. Patient characteristics are presented in the Table.
Functional Outcomes
Baseline BCVA was similar in both groups since this parameter was adjusted: 45.2 letters in the SRDþ group and 45.3 letters in the SRDÀ group. The mean change in BCVA score from baseline to M12 was þ11 letters in the SRDþ group versus þ12 letters in the SRDÀ group (P ¼ 0.8; Fig. 1 ).
Anatomical Outcomes
The mean baseline CRT was 625 6 130 lm in the SRDþ group versus 480 6 79 lm in the SDRÀ group (P ¼ 0.00001). The mean CRT change from baseline to M12 was significantly decreased in the SRDþ group (À234 lm) compared to the SRDÀ group (À130 lm; P ¼ 0.003; Fig. 2 ). The mean CRT at M12 was 391 lm in the SRDþ group versus 350 lm in the SRDÀ group. At M12, the SRD was not resolved in 25.6% of patients in the SRDþ group.
Number of Ranibizumab Intravitreal Injections
The mean number of ranibizumab injections was similar in both groups: 5.8 in the SRDþ group (range, 3-6) and 5.5 in the SRDÀ group (range, 3-6) over the first year.
Responder Profiles at M12
The proportion of patients who gained more than 15 letters at M12 was 38.5% (n ¼ 16) in the SRDþ group versus 41% (n ¼ 15) in the SRDÀ group (P ¼ 0.99). The proportion of patients whose BCVA was >70 letters was 25.64% (n ¼ 16) in the SRDþ group versus 41% (n ¼ 10) in the SRDÀ group (P ¼ 0.75). The proportion of patients whose CRT was <300 lm at M12 was 33.33% (n ¼ 13) in the SRDþ group versus 48.7% (n ¼ 19) in the SRDÀ group (P ¼ 0.75). The range of CRT was 170 to 650 lm at 12 months in the SRDþ group and 178 to 646 lm in the SRDÀ group.
DISCUSSION
Serous retinal detachment is common in DME [5] [6] [7] with an incidence of 13% to 45%. [6] [7] [8] The presence of SRD has recently been identified as a factor associated with a better prognosis in case of DME treated with monthly ranibizumab. 15 In the present study, we investigated the effect of SRD in DME during ranibizumab treatment with a PRN regimen, on the VA gain at 12 months in a real-life setting and failed to show an association between the presence of SRD and the 1-year visual outcome.
In the literature, a few papers have studied the effect of SRD on DME. 13, [16] [17] [18] [19] Before anti-VEGFs were indicated for the treatment of DME, Gaucher et al. 13 in 2008 have found that SRD height did not correlate with the VA or retinal thickness in case of DME. Nowadays, there is no clear conclusion about the prognostic value of SRD associated with DME. Shukla et al. 20 have considered SRD as a good predictor of DME resolution on triamcinolone, whereas Shimura et al. 16 in 2011 have not found such an association. Since the introduction of anti-VEGFs for the treatment of DME, some authors have attempted to identify predictive factors for visual outcome based on the different OCT patterns in DME after intravitreal injection of bevacizumab (IVB).
18,21,22 Shimura et al. 21 in 2013 and Kim et al. 22 in 2011 have shown that intravitreal bevacizumab was more effective on the diffuse retinal thickening type than on the cystoid macular edema or SRD type of DME. In contrast, Koytak et al. 18 in 2013 have shown that the SRD type was associated with a greater reduction in central foveal thickness than the diffuse retinal thickening type.
The presence of subretinal fluid during DME treatment with ranibizumab has already been investigated in a post hoc analysis of the RISE and RIDE studies, showing that patients with baseline SRD are more likely to achieve a BCVA >20/40 after 2 years of follow-up on monthly ranibizumab 0.3-or 0.5-mg injections. 15 In a previous study, 9 we have also found that SRD was associated with a higher gain of VA after 6 months of treatment. In this previous study, the visual gain was þ21 letters in the SRDþ group versus þ7.8 letters in the SRDÀ group (P ¼ 0.004), after the same number of injections. However, the baseline BCVA was significantly different: 39 letters in the SRDþ group versus 52 letters in the SRDÀ group. The lower baseline BCVA could have, in this study, artificially improved the final visual gain as previously shown by Dugel et al. 23 In the present study, after adjusting the baseline BCVA between both groups, we did not find any difference in VA gain between SRDþ and SRDÀ patients treated for DME. Taken together, all these findings suggest that SRD is not associated with a higher VA gain but rather with a lower baseline VA that is known in the literature as a negative predictive factor for final VA. 23 Moreover in our series, patients without SRD tended more frequently to achieve a threshold VA of 20/40 at the end of the follow-up than patients with baseline SRD. This result does not support those of the RISE and RIDE subanalysis that has shown a higher proportion of patients with a VA over 20/40 in cases with baseline SRD with odds ratio of 2.88 after 2 years of follow-up on monthly ranibizumab. Furthermore, in our series, patients without SRD also tended to have more often a flat retina at 1 year (<300 lm) despite a longer DME duration before treatment. We could thus assume that SRD associated with DME could be a sign of DME severity, supporting early DME treatment before patients experience a severe vision loss, potentially associated with an increased need for intravitreal injections like in the RISE and RIDE studies to achieve a good visual outcome.
In terms of anatomical features, the mean baseline CRT was significantly higher in the SDRþ group than in the SRDÀ group FIGURE 2. Mean change in CRT from baseline to M12 (secondary endpoint). Bars correspond to SE ¼ standard error, and * corresponds to P < 0.05.
(625 6 130 lm versus 480 6 79 lm, P ¼ 0.00001). However, after three injections and at the end of the follow-up, the mean CRT was not statistically different between both groups (391 lm versus 350 lm, respectively, P ¼ 0.15). Moreover, the percentage of patients with a CRT <300 lm and showing a resolution of the foveal pit was significantly higher in the SDRÀ group than in the SRDþ group. This supports the fact that patients in the SRDþ group could have required more intravitreal injections, but at the time when patients were treated, the retreatment indications were only based on the VA and not on the presence of fluid.
Further prospective randomized studies on larger patient cohorts are needed to confirm these results since the main limitations of our study are its retrospective design and small sample size.
In conclusion, SRD does not seem to be a good prognostic factor during DME treatment with ranibizumab with a PRN regimen and in a real-life setting. We failed to find better visual outcomes in cases of SRD unlike what has been observed in a post hoc analysis of a large cohort of patients on monthly treatment. We could assume that the previously identified good prognosis associated with SRD could be due to the high frequency of injections, and that we failed to find the same results because patients were injected with a PRN regimen. To achieve the good visual outcomes found in RISE and RIDE in our patients with SRD, we could assume that a more aggressive treatment would have been needed.
